The efficacy of the wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma

Jenny L. Pokorny, David Calligaris, Shiv K. Gupta, Dennis O. Iyekegbe, Dustin Mueller, Katrina K. Bakken, Brett L. Carlson, Mark A. Schroeder, Debra L. Evans, Zhenkun Lou, Paul A. Decker, Jeanette E. Eckel-Passow, Vincenzo Pucci, Bennett Ma, Stuart D. Shumway, William F. Elmquist, Nathalie Y.R. Agar, Jann N. Sarkaria

Research output: Contribution to journalArticle

52 Scopus citations

Fingerprint Dive into the research topics of 'The efficacy of the wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma'. Together they form a unique fingerprint.

Medicine & Life Sciences